Get the Stockscreener App
1.895
13.47%
-0.295
After Hours:
1.95
0.055
+2.90%
Editas Medicine Inc stock is traded at $1.895, with a volume of 1.83M.
It is down -13.47% in the last 24 hours and up +13.81% over the past month.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
See More
Previous Close:
$2.19
Open:
$2.175
24h Volume:
1.83M
Relative Volume:
1.05
Market Cap:
$184.99M
Revenue:
$32.31M
Net Income/Loss:
$-237.09M
P/E Ratio:
-0.658
EPS:
-2.88
Net Cash Flow:
$-219.11M
1W Performance:
-13.07%
1M Performance:
+13.81%
6M Performance:
-31.34%
1Y Performance:
-7.56%
1-Day Range:
$1.89
$2.175
1-Week Range:
$1.89
$2.285
52-Week Range:
$0.9101
$4.5372
Editas Medicine Inc Stock (EDIT) Company Profile
Name
Editas Medicine Inc
Sector
Industry
Phone
617-401-9000
Address
11 HURLEY ST., CAMBRIDGE, MA
Compare EDIT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
1.895 | 213.78M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-28-25 | Initiated | H.C. Wainwright | Buy |
| Dec-16-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-13-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-13-24 | Downgrade | Stifel | Buy → Hold |
| Dec-13-24 | Downgrade | Truist | Buy → Hold |
| Dec-11-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Underperform |
| Nov-06-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Aug-08-24 | Upgrade | BofA Securities | Neutral → Buy |
| May-09-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Oct-24-23 | Upgrade | Citigroup | Neutral → Buy |
| Oct-18-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-29-23 | Upgrade | Stifel | Hold → Buy |
| Jun-12-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-13-22 | Initiated | Citigroup | Neutral |
| Dec-06-22 | Resumed | Credit Suisse | Neutral |
| Nov-18-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-18-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-22 | Initiated | BofA Securities | Neutral |
| Oct-19-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Sep-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-09-21 | Upgrade | Truist | Hold → Buy |
| Aug-05-21 | Upgrade | Evercore ISI | Underperform → Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Apr-16-21 | Initiated | Goldman | Sell |
| Mar-22-21 | Initiated | Credit Suisse | Outperform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-26-21 | Downgrade | Truist | Buy → Hold |
| Jan-19-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-07-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-10-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-03-20 | Initiated | Robert W. Baird | Underperform |
| Jun-18-20 | Resumed | SunTrust | Buy |
| Feb-21-20 | Initiated | Wells Fargo | Equal Weight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-10-18 | Initiated | Guggenheim | Neutral |
| Sep-21-18 | Initiated | Raymond James | Outperform |
| May-15-18 | Reiterated | Chardan Capital Markets | Buy |
| Feb-13-18 | Initiated | CLSA | Underperform |
| Jan-23-18 | Upgrade | SunTrust | Hold → Buy |
| Jul-14-17 | Initiated | SunTrust | Hold |
| Mar-28-17 | Initiated | Chardan Capital Markets | Buy |
| Aug-10-16 | Upgrade | Jefferies | Hold → Buy |
| Jun-02-16 | Initiated | Jefferies | Hold |
| Feb-29-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-29-16 | Initiated | JP Morgan | Neutral |
| Feb-29-16 | Initiated | Morgan Stanley | Equal-Weight |
View All
Editas Medicine Inc Stock (EDIT) Latest News
Editas Medicine SVP Parison sells $957 in stock By Investing.com - Investing.com Australia
Editas Medicine SVP Parison sells $957 in stock - Investing.com
Editas Medicine (NASDAQ:EDIT) CEO Gilmore Neil O'neill Sells 5,394 Shares - MarketBeat
EDIT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Editas Medicine at TD Cowen: Strategic Focus on In Vivo CRISPR - Investing.com Canada
EDIT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Editas Medicine Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Editas Medicine (EDIT) Expected to Announce Earnings on Wednesday - MarketBeat
Editas Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Gene editor Editas brings its story to Boston and Miami investors - Stock Titan
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Editas Medicine (NASDAQ:EDIT) Shares Pass Below 50-Day Moving AverageWhat's Next? - MarketBeat
Can Editas Medicine Inc. ride the EV waveQuarterly Profit Report & Weekly Setup with High ROI Potential - mfd.ru
Market Moves: Whats the MACD signal for CARGWeekly Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Signal Recap: Can Editas Medicine Inc disrupt its industryBear Alert & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Aug Movers: Can Editas Medicine Inc. outperform in the next rallyEarnings Risk Report & Reliable Volume Spike Trade Alerts - mfd.ru
Why Editas Medicine Inc. (8EM) stock could be next leaderJuly 2025 Trade Ideas & AI Driven Price Predictions - mfd.ru
Editas Medicine’s Volatile Comeback: Can CRISPR Hype Outrun Clinical Risk? - AD HOC NEWS
Editas Medicine (NASDAQ:EDIT) Share Price Crosses Below Fifty Day Moving AverageTime to Sell? - MarketBeat
Analyst Downgrade: Can Editas Medicine Inc grow without external fundingMarket Performance Summary & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Can Editas Medicine Inc. stock sustain revenue growth2025 Investor Takeaways & Community Shared Stock Ideas - mfd.ru
Can Editas Medicine Inc. disrupt its industryWeekly Gains Report & Daily Momentum Trading Reports - mfd.ru
Companies Like Editas Medicine (NASDAQ:EDIT) Could Be Quite Risky - Yahoo Finance
Gene Editing Market Growth in Future Scope 2026-2033| CRISPR - openPR.com
Editas Medicine (NASDAQ:EDIT) Share Price Crosses Below 50 Day Moving AverageHere's What Happened - MarketBeat
Editas Medicine achieves significant LDL reduction with EDIT-401 therapy - Traders Union
Editas Medicine, Inc. (NASDAQ:EDIT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Individual investors who hold 55% of Editas Medicine, Inc. (NASDAQ:EDIT) gained 14%, institutions profited as well - simplywall.st
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.
Street Watch: Is Editas Medicine Inc stock a falling knife or bargain buy2025 Major Catalysts & Daily Oversold Bounce Ideas - baoquankhu1.vn
Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50 Day Moving AverageWhat's Next? - MarketBeat
Hedge Fund Bets: Can Editas Medicine Inc disrupt its industry2025 Buyback Activity & Precise Trade Entry Recommendations - baoquankhu1.vn
Fed Watch: Can Editas Medicine Inc. maintain sales growthJuly 2025 Patterns & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Recap Report: Can Editas Medicine Inc. stock surprise with earnings upsidePortfolio Risk Summary & Low Risk Investment Opportunities - Bộ Nội Vụ
Retail Surge: Is Editas Medicine Inc stock affected by interest rate hikesJuly 2025 Decliners & Real-Time Volume Analysis Alerts - Bộ Nội Vụ
Inflation Data: Will Editas Medicine Inc stock remain a Wall Street favoriteJuly 2025 Recap & Detailed Earnings Play Strategies - moha.gov.vn
Is Editas Medicine Inc. stock overvalued by current metricsQuarterly Risk Review & AI Powered Trade Plan Recommendations - ulpravda.ru
Can Editas Medicine Inc. stock surprise with earnings upsideQuarterly Market Summary & Free Safe Entry Trade Signal Reports - Улправда
Will Editas Medicine Inc. stock remain a Wall Street favoriteMarket Sentiment Review & AI Driven Price Predictions - Улправда
Is Editas Medicine Inc. stock in correction or buying zone2025 Growth vs Value & Reliable Entry Point Alerts - Улправда
Can Editas Medicine Inc. stock attract ESG capital inflowsWall Street Watch & Real-Time Buy Signal Notifications - ulpravda.ru
Is Editas Medicine Inc. stock affected by interest rate hikesShort Setup & Reliable Volume Spike Trade Alerts - Улправда
Is Editas Medicine Inc. stock ready for breakout2025 Valuation Update & Free Expert Approved Momentum Trade Ideas - Улправда
Street Watch: Can Editas Medicine Inc. (8EM) stock expand revenue streams2025 Geopolitical Influence & Free Long-Term Investment Growth Plans - Улправда
Aug Catalysts: Why Editas Medicine Inc. (8EM) stock could rally stronglyQuarterly Profit Summary & Free Verified High Yield Trade Plans - Улправда
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Fibonacci Retracement Aligns with Support in Alka Securities LimitedMarket Sentiment Shifts & Free Realize Exceptional Returns - earlytimes.in
Editas Medicine (NASDAQ:EDIT) Stock Price Down 2.9%Should You Sell? - MarketBeat
Editas Medicine (EDIT) price target increased by 22.78% to 4.95 - MSN
Editas Medicine Stock Slides After-Hours On Bigger-Than-Expected Q4 Loss, But Retail Bulls Eye M&A Potential - MSN
Editas Medicine Inc Stock (EDIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):